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Clinical Case Presentation
A 25-year-oldAfricanAmerican woman who was 17
weeks pregnant presented in the emergency room with
vaginal bleeding. This was her first pregnancy and she
denied ever receiving a transfusion. She had no history
of blood bank testing at this hospital.
Immunohematologic Evaluation and Results
Forward and reverse ABO and D typing was
performed using a standard test tube method, and the
patient was found to be group A, D– (Table 1). No
discrepancy was observed.
The antibody detection test using the gel method
(ID-MTS anti-IgG cards and 0.8% Selectogen reagent
RBCs;Ortho-Clinical Diagnostics,Raritan,NJ) produced
agglutination (2+) with cell I, and no agglutination (0)
with cell II (Table 2).
An RBC panel used for antibody identification (0.8%
Resolve Panel A,Ortho-Clinical Diagnostics) was tested
using gel. Eight of 11 reagent RBC samples were
reactive, with seven of those samples demonstrating
mixed cell agglutination and one sample demonstrating
2+ agglutination (Table 3). The patient’s auto-control
run in parallel with the RBC panel was negative.
A second RBC panel (0.8% Resolve Panel B, Ortho-
Clinical Diagnostics) was tested using gel and
demonstrated agglutination with only one RBC sample
producing mixed cell agglutination (Table 4).
Additional selected reagent RBCs were tested using
gel to exclude all other commonly encountered anti-
bodies. Sufficient rule-outs were obtained (Table 5).
The inability to definitively confirm antibody
specificity and the observance of numerous mixed cell
reactions prompted testing with alternative antibody
detection methods. An antibody detection test using
PEG (PeG and Panocreen I and II; Immucor/Gamma,
Norcross, GA) was performed and resulted in
agglutination (2+) at the IAT phase only with both
screening cells (Table 6).
A cold panel consisting of antibody detection cells
(Panocreen I and II, A1 and A2 RBCs, Referencells-4,
Immucor/Gamma),group O cord RBCs,and the patient’s
RBCs was performed. If the mixed cell reactions were
caused by a cold reacting antibody,the cold panel would
aid in establishing whether the antibody is autoimmune
or alloimmune in nature, and would confirm its
specificity. The immediate spin phase was nonreactive
with all RBC samples, but the 15-minute room
temperature incubation produced agglutination (2+)
with the antibody detection RBCs,A1 RBCs,andA2 RBCs
(Table 7). Agglutination was observed with all RBC
samples tested at 18°C and 4°C.
A selected RBC panel (Panocell, Immucor/Gamma)
was tested using PEG,which demonstrated agglutination
(1+ to 2+) at the IAT phase with Le(a+) or Le(b+) RBC
samples. At least one expression of all other commonly
encountered antigens was represented on Le(a–b–) RBC
samples. All were nonreactive at all phases (Table 8).
Interpretation
This case describes classic identification of anti-Lea
and anti-Leb, demonstrating seemingly nonspecific
reactivity at first glance yet highly suggestive reactivity
after further review of gel testing. The reactivity of most
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Table 1. Standard test tube method for forward and reverse ABO and
D typing
Forward Reverse
Additive Anti-A Anti-B Anti-D A1 Cells B Cells
Immediate Spin 4+ 0 0 0 4+
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Identifying antibodies to Lea and Leb
Le(a+) or Le(b+) RBC samples on the initial antibody
identification panel in conjunction with the patient’s
diagnosis suggested the presence of both antibodies and
warranted further testing to identify them by alternative
methods. Both anti-Lea and anti-Leb were confirmed by
tube testing using PEG. These serologic findings are
supported by the reactivity of the cold panel at the 15-
minute room temperature phase with RBC samples
known or likely to express the Lea and Leb as opposed
to nonreactivity with cord RBCs likely to lack or have
weak expressions of both antigens.
Discussion
Anti-Lea and -Leb are usually IgM in nature, with
optimal reactivity at room temperature or lower. As
previously stated, the ID-MTS gel system was used as the
primary antibody detection method and uses anti-IgG
specific cards that are not known to be sensitive for IgM
antibodies. However, IgM antibodies can yield positive
reactions in anti-IgG cards if antibodies and RBCs
agglutinate in the card’s reaction chamber before centri-
fugation.1 Presumably, if not all RBCs in the reaction
chamber agglutinate, a mixed cell reaction could occur.
Table 3. Antibody identification panel
1) R1R1 + + + 0 0 + 0 + + + + 0 + + 0 + 0 + 0 0 0 + + + + 0
2) R1R1 + + 0 0 0 + 0 + + + 0 0 + 0 0 0 0 + 0 0 + + + + + 0
3) R2R2 + 0 0 + + 0 0 0 + + + 0 + 0 0 0 0 + 0 0 + + 0 + 0 0
4) R0r + 0 0 0 + + + + + 0 + 0 + + + 0 0 + 0 0 0 0 0 + + MC
5) r′r 0 + 0 0 + + + + + 0 + 0 + + + 0 0 + 0 0 + 0 + 0 + MC
6) r′′r 0 0 0 + + + + + + + + 0 + + 0 + 0 + 0 0 0 + + + + 2+
7) rr 0 0 0 0 + + + + + 0 + 0 + + + 0 + + 0 0 0 + 0 + + MC
8) rr 0 0 0 0 + + + + + + + 0 + 0 + 0 0 + 0 0 + 0 + 0 + MC
9) rr 0 0 0 0 + + + + 0 + 0 0 + + + 0 0 + 0 0 0 + + + + MC
10) rr 0 0 0 0 + + + 0 + 0 + 0 + + 0 + 0 + 0 0 + 0 0 + + MC
11) R1R1 + + 0 0 0 + 0 + + + + 0 + 0 + 0 + + 0 0 0 + + + + MC
12) Patient 0
MC = mixed cell agglutination
Rh MNS Kell GEL, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IAT
Lewis Duffy Kidd
Table 4. Alternative antibody identification panel
12) rr 0 0 0 0 + + + + 0 + 0 0 + + 0 + 0 + 0 0 + 0 + 0 + 0
13) rr 0 0 0 0 + + + + 0 + 0 0 + 0 0 + 0 + 0 0 0 + + 0 + 0
14) rr 0 0 0 0 + + + + + 0 + 0 + + 0 + 0 + 0 0 + + 0 + 0 0
15) R2R2 + 0 0 + + 0 0 + + + + 0 + 0 0 + 0 + 0 0 + 0 + 0 + 0
16) R2R2 + 0 0 + + 0 0 + 0 + + 0 + 0 0 + 0 + 0 0 + 0 0 + 0 0
17) R2R2 + 0 0 + + 0 0 + + 0 + 0 + 0 + 0 0 + 0 0 + 0 0 + + 0
18) R1R1 + + 0 0 0 + 0 0 + + + 0 + S + 0 0 + 0 0 0 + + 0 + MC
19) R1R1 + + 0 0 0 + 0 0 + 0 + 0 + + 0 + + + 0 0 + 0 0 + + 0
20) Rzr′ + + 0 + 0 + 0 + 0 + + 0 + 0 0 + 0 + 0 0 + 0 0 + + 0
21) r′′r 0 0 0 + + + + + + 0 + 0 + 0 0 + + + 0 0 + + + + + 0
22) R2R2 + 0 0 + + 0 0 0 + 0 + 0 + + 0 + + 0 0 0 + + + + + 0
MC = mixed cell agglutination
Rh MNS Kell GEL, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IAT
Lewis Duffy Kidd
Table 2. Antibody detection test
1) R1R1 + + 0 0 0 + 0 + + + + 0 + + + 0 + + 0 0 + 0 0 + + 2+
2) R2R2 + 0 0 + + 0 0 + 0 + 0 0 + + 0 + 0 + 0 0 + + + 0 + 0
Rh MNS Kell GEL, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IAT
Lewis Duffy Kidd
Of the 29 total reagent panel cells tested using gel,
two cells were Le(a–b–). Both these RBC samples were
nonreactive. There were 13 reactive RBC samples,all of
which expressed either Lea or Leb. All but two of the
reactive RBC samples demonstrated mixed cell reac-
tivity,which is consistent with IgM antibodies.
Although the cold panel demonstrated agglutination
with all RBC samples tested at the latter phases of 18°C
and 4°C, consistent with a cold autoantibody, the room
temperature agglutination observed on the antibody
detection RBCs, A1 RBCs, and A2 RBCs suggests the
presence of antibody or antibodies that are alloimmune
in nature. The manufacturer listed the antibody de-
tection RBCs as having expressed either Lea or Leb. The
A1 and A2 RBCs were manufactured from a pool of
donors, known only to be negative for D, C, and E.2 All
other non-ABO blood group antigens, including Lea and
Leb, could be expressed on these reagent RBCs. Lewis
system antigens are poorly developed at birth, explain-
ing the nonreactivity of the cord blood RBCs.3
Both antibody detection RBC samples agglutinated
(2+) at the IAT phase of a PEG-IAT. Some IgM antibodies
are known to react at PEG-IAT, including those in the
Lewis system.1 The decision was made to test a panel of
RBC samples using a PEG additive under the belief that
the 2+ agglutination observed with the antibody de-
tection RBC samples indicated that consistent reactivity
on Le(a+) and Le(b+) RBCs would be attainable. The
RBCs selected for the PEG panel consisted of three
Le(a+), three Le(b+), and one with double-dose ex-
pression of all other commonly encountered antigens. A
double-dose RBC for K (K+k) was unavailable so a
single-dose (K+k+) RBC sample was substituted.
Although all other antibodies had already been excluded
using gel, the Le(a–b–) RBC samples were tested as a
negative control to exclude any other antibodies that
may only react by PEG-IAT. The negative reactions on
these RBCs ensure the reactivity observed on all of the
Le(a+) and Le(b+) RBCs was attributable to anti-Lea
and -Leb.
Had the PEG testing been nonreactive at all phases,
the next logical step would have been to test the same
selected cell panel using a 15-minute room temperature
incubation. The results of the cold panel suggest reac-
tivity with only the Le(a+) and Le(b+) RBCs would have
been observed.
In the absence of sufficient Le(a–b–) reagent RBCs,
the presence of Lewis antibodies can be confirmed by
incubating the patient’s plasma with commercially
available Lewis substance before testing against Le(a+)
or Le(b+) panel RBCs. Lewis substance contains the Lea
and Leb antigens,which neutralize the antibodies in the
patient’s plasma. After neutralization, reactivity with
Le(a+) or Le(b+) panel RBCs would not be expected.
However,validation of testing Lewis-neutralized plasma
using the gel method has not been documented.
Antibodies to Lewis antigens are common in
pregnant patients. Drastic increases in lipoprotein levels
60 I M M U N O H E M A T O L O G Y, VO L U M E 2 4 , N U M B E R 2 , 2 0 0 8
L. ERNSTER
Table 7. Cold panel antibody detection test
Short Cold Panel
Phase: IS RT 18°C 4°C
SC I 0 2+ 3+ 3+
SC II 0 2+ 3+ 3+
Auto 0 0 W+ 3+
0 Cord Cells 0 0 2+ 3+
A1 Cells 0 2+ 3+ 3+
A2 Cells 0 2+ 2+ 3+
Table 5. Additional cells
1) R1R1 + + 0 0 0 + 0 + 0 0 + 0 + S + 0 0 + 0 0 + 0 + 0 0 0
2) R1R1 + + 0 0 0 + 0 + + + 0 0 + + + 0 0 + 0 0 + + 0 + + MC
3) R1R1 + + + 0 0 + 0 + + + + 0 + + 0 + + + 0 0 + + + 0 + W+
4) R1R1 + + + 0 0 + 0 + + + + 0 + + 0 + 0 + 0 0 0 + 0 + + 0
5) R1R1 + + + 0 0 + 0 + 0 + + 0 + 0 + 0 0 + 0 0 + 0 + + + MC
MC = mixed cell agglutination
Rh MNS Kell GEL, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IAT
Lewis Duffy Kidd
Table 6. PEG antibody detection test
1) R1R1 + + 0 0 0 + 0 + + 0 + 0 + + 0 + + + 0 0 0 + + + + 0 NH 2+ NT
2) R2R2 + 0 0 + + 0 0 + + + + 0 + 0 + 0 0 + 0 0 + + 0 + + 0 NH 2+ NT
NH = no hemolysis NT = not tested
Rh MNS Kell PEG, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IS 37 IAT CC
Lewis Duffy Kidd
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Identifying antibodies to Lea and Leb
can cause a patient that normally expresses Lewis on
her RBCs to lose her antigen expression, allowing for
the formation of naturally occurring antibodies to the
Lea and Leb determinants.4 In addition, approximately
22 percent of African Americans are genetically Le(a–
b–).5 The patient’s admitting diagnosis and ethnicity
support antibodies to the Lewis system.
Because anti-Lea and -Leb are usually clinically
insignificant antibodies,5 RBCs that are crossmatch-
compatible in a 37°C test (i.e., gel or PEG-IAT) are
suitable for transfusion. Typing units of RBCs for either
Lea or Leb is not necessary.3
Closing Comments
Many different factors can aid in the identification of
unexpected antibodies. This patient’s diagnosis, eth-
nicity, and unusual reactivity with the initial antibody
identification panel were highly suggestive of anti-Lea
and -Leb. Each antibody identification method has its
own nuances. Knowing what unexpected results can
indicate and correlating them to the patient’s history
and clinical situation can reduce unnecessary testing
and lead to more efficient problem resolution.
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Table 8. PEG test on selected cell panel
1) rr 0 0 0 0 + + + + 0 + 0 0 + 0 0 0 0 + 0 0 0 + + + + 0 NH 0 
2) rr + + 0 0 + + + 0 + 0 + 0 + + 0 0 0 + 0 0 0 0 + 0 0 0 NH 0 
3) R1R1 + + 0 0 0 + 0 + 0 + + 0 + + 0 0 + + 0 0 + + + + + 0 NH 0 
4) R2R2 + 0 0 + + 0 0 + 0 + + 0 + 0 0 0 0 + 0 0 + 0 + + + 0 NH 0 
5) r′r 0 + 0 0 + + + + + 0 + 0 + + 0 + 0 + + 0 + 0 + 0 + 0 NH 2+ NT
6) r′′r 0 0 0 + + + + + 0 + 0 0 + + 0 0 0 + 0 0 0 + 0 + 0 0 NH 0 
7) rr 0 0 0 0 + + + + + 0 + 0 + 0 + 0 + + 0 0 0 0 0 + + 0 NH 2+ NT
8) rr 0 0 0 0 + + + + 0 + + 0 + + 0 + 0 + 0 0 + 0 0 + 0 0 NH 1+ NT
9) rr 0 0 0 0 + + + + 0 + + 0 + + 0 + 0 + 0 0 0 0 + + 0 0 NH 1+ NT
10) rr 0 0 0 0 + + + 0 + 0 + 0 + + + 0 0 + 0 + 0 0 + + 0 0 NH 2+ NT
11) R0r + 0 0 0 + + + 0 + + + + + + + 0 + + 0 0 0 0 + 0 + 0 NH 1+ NT
12) Patient 0 NH 0 
NH = no hemolysis NT = not tested
Rh MNS Kell PEG, 15′Lu P
D C Cw E c e f M N S s Lua Lub P1 Lea Leb K k Kpa Jsa Fya Fyb Jka Jkb Xga IS 37 IAT CC
Lewis Duffy Kidd
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